anastrozole men

Based on the results of animal experiments drug overdose can cause severe gastrointestinal intolerance. Careful monitoring of the function of vital organs and hemostasis (bleeding time). In case of overdose recommended gastric lavage and the use of general supportive measures.

The interaction with other drugs
Some drugs anastrozole can interact with them through ticlopidine antiplatelet properties. This substance such as aspirin and non-steroidal anti-inflammatory drugs anastrozole men, clopidogrel, tirofiban, eptifibatide, abciximab and iloprost. The simultaneous use of several inhibiting platelet aggregation tools, as well as their combination with heparin, oral anticoagulants and thrombolytics can substantially increase the risk of bleeding, so should be subject to regular clinical and laboratory monitoring.

Combinations requiring special care:
Theophylline (base and salts) and aminophylline:
Increase in plasma theophylline levels with risk of overdosage (decrease in plasma clearance of theophylline). Clinical monitoring is required, as well as measurement of plasma levels of theophylline. The dosage of theophylline should be modified if necessary in the course of ticlopidine treatment and after its completion.

Phenytoin:
Increased phenytoin plasma levels with signs of overdose (inhibition of metabolism of phenytoin). Requires clinical monitoring and measuring plasma levels of phenytoin.

Tacrolimus:
Concentrations of cyclosporin in the anastrozole men blood drop. Cyclosporin dose should increase its concentration in the control. After the abolition ticlopidine dose should be reduced.

Digoksii:
Combined use of digoxin reduces by 15% the concentration of the latter in the blood plasma.

Other interactions:
Antacids, reducing the absorption, reduces the concentration of ticlopidine in plasma by 18%; concomitant use with cimetidine may lead to slower elimination ticlopidine; mielotoksichsekie drugs increase the risk of suppression of bone marrow hematopoiesis.

Cautions
Ticlopidine may cause hematologic or hemorrhagic side effects. (see. “Side effects”).

Hematologic disorders are mainly associated with white blood cells. In most cases, these side effects occur during the first three months of treatment. Sometimes there are severe cases (severe neutropenia, agranulocytosis), which can lead to death.

Severe hematologic outcomes or hemorrhagic side effects more likely to occur under the following conditions:
– Failure to comply with control measures, late diagnosis and inadequate therapeutic intervention;
– The combined use of anticoagulants or platelet aggregation inhibitors such as aspirin .

Hematological control
at the beginning of treatment should be carried out differential blood count (including platelet count), then it should be repeated every two weeks for the first three months of therapy. If treatment is discontinued during the first three months, within two weeks after discontinuation of treatment necessary to monitor neutrophils and platelets.

Control of hemostasis
Ticlopidine should be used with caution in risk of bleeding (see. “Interactions with other medicinal products”).

If the patient to surgery, in the case of undesirable effects of platelet suppression, treatment should be discontinued for at least ten days prior to surgery.

In the case of emergency surgery to reduce the risk of bleeding and bleeding time reduction can use three methods, individually or together:
1) administering 0.5-1.0 mg / kg methylprednisolone intravenously, which may be repeated;
2) administering desmopressin at a dose 0.2-0.4 mg / kg;
3) transfusion of fresh platelets in the platelet concentrate unit form.

Clinical control
All patients taking ticlopidine, should be made aware that the appearance of high temperature, sore throat, ulcers in the mouth, long or unusual bleeding, bruising, bloody vomit and stool (melena) requires the patient immediate treatment to the doctor .

The clinical diagnosis of thrombotic thrombocytopenic purpura anastrozole mencan be put in the presence of thrombocytopenia, hemolytic anemia and neurological symptoms, kidney dysfunction and high temperature.Home can be a surprise. Most cases were reported during the first eight weeks after initiation of therapy. Prognosis is very serious (known deaths from TTP).

The drug should be used with caution in patients with impaired liver function, and in the case of hepatitis or jaundice need to stop treatment.

what is anastrozole

Ticlopidine inhibits platelet aggregation. It causes a dose-dependent inhibition of platelet aggregation and release of certain platelet factors, and prolongation of bleeding time.

The drug has no significant activity in vitro, but only in vivo. There was identified ticlopidine actively circulating metabolites.

Ticlopidine inhibits platelet aggregation by inhibiting what is anastrozole binding of fibrinogen to the platelet membrane. Unlike aspirin, it does not inhibit cyclooxygenase. Cyclic  platelets apparently not play a role in the mechanism of action.

After discontinuation of therapy in most patients with bleeding time and other platelet function returns to normal within one week. Inhibition of platelet aggregation occurs within two days from the beginning of the use of ticlopidine twice a day.

The maximum effect is reached at 5-8 days of treatment at a dose of 250 mg twice a day. The therapeutic dose of ticlopidine inhibits . Lower doses cause proportionally less inhibition of platelet aggregation.

Pharmacokinetics
Following oral administration a unit dose disposable ticlopidine absorption occurs fast, with the achievement of the maximum plasma level after 2 hours after administration.

Absorption is almost complete. Appointment of ticlopidine after meals improves bioavailability.

Stable in plasma drug levels are achieved after 7-10 days of administration of 250 mg twice a day. The average what is anastrozole of ticlopidine at sustainable levels is approximately 30-50 hours. However, no inhibition of platelet aggregation depends on the concentration level of the drug in plasma.

Ticlopidine is metabolized in the liver. After oral administration of the drug, radiolabeled, 50-60% was found in the urine of 23-30% – in the feces.

Elderly patients:
The main clinical trials were conducted with the participation of a group of patients with mean age 64. Pharmacokinetics ticlopidine modified in elderly patients, but its pharmacological and therapeutic activity at a dose of 500 mg per day, regardless of the age.

Indications
– prevention of arterial thrombotic events (stroke, myocardial infarction, vascular death) in patients with ischemic stroke caused by cerebral atherosclerosis.
– Prevention of ischemic events, particularly coronary, in patients with coronary heart disease  in patients with chronic diseases of the arteries of the lower extremities (intermittent claudication).
– Prevention of re-thrombosis in chronic hemodialysis.

Contraindications
– Allergy to ticlopidine in history.
– Haemorrhagic diathesis.
– Diseases with a tendency to bleeding (gastric ulcer or duodenal ulcer, hemorrhagic stroke).
– Diseases of the blood with prolongation of bleeding time.
– Hematologic abnormalities (leukopenia, thrombocytopenia or agranulocytosis in history) .
– Severe hepatic impairment.
– Pregnancy and lactation. The caution used in patients with impaired hepatic function (see “Special instructions”.) with renal insufficiency, surgical interventions, trauma and other pathological conditions with the risk of bleeding. Efficacy and safety of ticlopidine in children has not been established.

Dosage and administration
for adults only.

For oral administration.

For all indications drug administered in a dose of 250 mg 2 times a day, during or after meals. The maximum daily dose may be 1 gram (can be assigned only for a short period of time).

In chronic renal failure dose reduction is necessary

Side effects: From the side of hematopoiesis system leukopenia (neutropenia, agranulocytosis), pancytopenia, bone marrow aplasia (especially pronounced in elderly patients), hemolytic anemia, thrombocytopenia (isolated or conjugated with hemolytic anemia). Very rarely thrombotic thrombocytopenic purpura.

On the part of the hemostatic system
Hemorrhagic manifestations.

From the gastrointestinal tract
Nausea, diarrhea, pain in the stomach, rarely cytolytic and / or cholestatic hepatitis. Isolated or combined increased alkaline phosphatase, transaminases and bilirubin during the first 4 months of treatment.

With the skin side
polymorphic skin rash, often accompanied by itching. In very rare cases, there is erythema multiforme.

Allergic reactions
Very rarely observed various forms of immune-alllergicheskih reactions: very rarely – anaphylactic reaction, angioedema, arthralgia, vasculitis, lupus syndrome, allergic pneumonitis, and nephropathy. We describe an extremely rare case of high temperatures.

From the nervous system
Dizziness, headache, tinnitus, asthenia.

Blood lipids
Within 1-4 months of treatment can be observed ticlopidine increase what is anastrozole and triglycerides in the serum 8-10%. With continued treatment further increase is observed. The proportion between the lipoprotein subfractions (especially between) remain unchanged. These clinical experiments have shown that this effect is not dependent on age, sex, or the presence of alcohol consumption, and diabetes does not affect the cardiovascular risk.

anastrozole side effects

As the metal complex compound  sterile and has anti-inflammatory and antimicrobial action.  Accelerates reparative processes in the skin and reduces inflammation (erythema, edema, infiltration), promotes the disappearance of itching. The presence of bound molecules and glycerol titanium atom in the molecule provides a protective  dehydrating, decongestant. local analgesic effect.

The molecule anastrozole side effects titanium atom chemically bound to glycerol, is a hub for constituting a complexing molecule fragments of the drug: glycerol and water. This interaction is determined bystructure providing its conductivity through biological tissue and its pharmacological properties. Promotes drugs through the skin and mucous membranes.

Pharmacokinetics
When topically  rapidly absorbed, distributed in the skin, subcutaneous tissue and underlying tissues. Do not metabolized. Provided intact kidneys 42% 48% through the intestines, 6.2% sweat glands, mucosal airway 3.8%. The rate of elimination of the drug 20-24 h. Does not accumulate in the body.

Indications for use :

– Bursitis, arthritis, tendonitis, tenosynovitis,
– psoriasis, atopic dermatitis, seborrheic eczema, dermatitis, scleroderma, lichen planus,
– as a topical radioprotective radiation therapy;
– conductor as medicaments.

Contraindications
: Hypersensitivity to anastrozole side effects, acute inflammatory diseases of the skin and mucous membranes, purulent wounds with pronounced symptoms of exudation.

Pregnancy and lactation
Insufficient data but use of the drug during pregnancy and lactation.

Dosage and administration
for local and external.

Apply to the affected skin and mucous thin layer 1-3 times a day. The course of treatment is individual, depends on the severity of the disease, the location and the severity of the process. The effect of the drug occurs within the first week of treatment. Possible repeated courses of treatment and long-term use within 2-3 months.

In applying the drug as a topical radioprotective agent for protection against radiation injuries applied thinly to the area of irradiation before a session and 12 hours thereafter. After the application is necessary to avoid contact with clothing, do not use occlusive dressings. In the presence of local radiation drug reactions used to its disappearance.

Side effects:
Rarely in the first few minutes after application to the skin or mucous possibly tingling, tingling, feeling of tightness, passing on their own and do not require discontinuation of therapy. When individual sensitivity may be local allergic reactions. In this case, the use anastrozole side effects stopped.

Overdose
Not recorded.

Interactions with other drugs
have been reported.

Cautions
As the gel complexing system, combined with a number of drug substances with different chemical composition and structure, and can be used as a basis for the preparation of soft medicinal forms.

anastrozole 1 mg

The drug should not be used during pregnancy except in cases where the potential benefit of treatment of the mother than the potential risk to the developing anastrozole 1 mg fetus. Lactation It is not known whether xylometazoline or its metabolites into breast milk, so the drug should not be used during breastfeeding.

Dosing and Administration

Children aged 2-6 years
• Unless directed otherwise by a single dose of the drug Tizin Xylo in the form of a nasal spray 0.05% dosed in each nostril 1-2 times a day.

Adults and children of school age (older than 6 years) • 3 times per day is administered by a single dose of the drug in the form of a Xylo Tizin 0.1% nasal spray metered into each nostril. The dose depends on the individual sensitivity of the patient and the clinical effect. Xylometazoline nasal dosing spray should not be used more than 5-7 days, if the doctor did not recommend a different treatment duration. After the completion of drug treatment may be administered again in just a few days. With regard to the duration of use in children always consult with a physician.

 

General recommendations for the introduction
Remove the protective cap. Before the first application several times to press the nozzle until a uniform cloud. The vial is ready for use.In applying the press once .The drug is inhaled through the nose. If possible, keep the spray bottle upright.Do not spray horizontally or downwards. After drinking a bottle cap close.

Side effect

Tizin Xylitol can cause transient slight irritation of the nose (burning), paresthesia, sneezing and hypersecretion in susceptible people.
In some cases, the drug may experience increased swelling of the nasal mucosa (reactive hyperemia).
Prolonged or frequent use of xylometazoline anastrozole 1 mg or use it in high doses can cause a burning sensation in the nose or mucous membranes dry and reactive congestion with the development of medical rhinitis.This effect can be observed even after 5-7 days after completion of treatment, and long-term use can cause irreversible damage to the mucous membrane with formation of crusts (dry rhinitis).
In very rare cases, there may be headache, insomnia or fatigue, depression (with a long used in high doses).
in rare cases, local intranasal application may be accompanied by systemic sympathomimetic effects, such as palpitations, tachycardia, arrhythmias, increased blood pressure, blurred vision.

Overdose

Symptoms of intoxication
overdose or accidental intake of the drug inside can cause the following symptoms: dilated pupils, nausea, vomiting, cyanosis, fever, spasms, tachycardia, cardiac arrhythmias, collapse, cardiac arrest, hypertension, pulmonary edema, respiratory failure, mental disorders.
In addition The following symptoms may occur: suppression of the central nervous system, accompanied by drowsiness, decrease in body temperature, bradycardia, shock-like hypotension, apnea and coma. intoxication Treatment Use of activated charcoal, gastric lavage, artificial respiration with the introduction of oxygen. To lower blood pressure used phentolamine 5 mg slow intravenous saline or 100 mg orally. Vasopressor agents are contraindicated. If necessary, apply anti-pyretic and anti-convulsants.

 

Interaction with other drugs

The simultaneous use of anastrozole 1 mg or tranylcypromine tricyclic antidepressants can cause increases in blood pressure due to cardiovascular effects of these substances.

special instructions

Prolonged use of sympathomimetic overdose and providing dekongestivnoe action may lead to reactive hyperemia nasal mucosa.
The phenomenon of recoil can cause airway obstruction that leads to the patient again begins to use the drug or even permanently. This can lead to chronic swelling (rhinitis medicamentosa), and eventually even to atrophy of nasal mucosa (ozena).
In the case of chronic rhinitis drug anastrozole 1 mg and 0.1% may be used only under medical supervision, given the risk atrophy of the nasal mucosa. Hyersensitivity to benzalkonium chloride, which is part of the drug as a preservative.
Do not exceed the recommended dose, especially in children and the elderly.

Effects on ability to drive and use machinery

With long-term treatment or use of the drug  at higher doses can not rule out the possibility of systemic effects on the cardiovascular system that may impair the ability to drive and use machinery.